Haim Barr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haim Barr has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Noa Lahav
The Weizmann Institute of Science
18 shared publicationsAlla H. Falkovich
Department of Chemical Research Support Weizmann Institute of Science Rehovot Israel
4 shared publications- David Margulies
Department of Chemical and Structural Biology Weizmann Institute of Science Rehovot Israel
4 shared publications - Denis Shpalter
Department of Chemical and Structural Biology Weizmann Institute of Science Rehovot Israel
4 shared publications - Ekaterina Petrovich‐Kopitman
Life Sciences Core Facilities Weizmann Institute of Science Rehovot Israel
4 shared publications Jiyun Zhu
The Weizmann Institute of Science ASAP Discovery Consortium The Wohl Drug Discovery institute Stanford University The Nancy and Stephen Grand Israel National Center for Personalized Medicine Stanford University
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wiley in Angewandte Chemie
Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions
Cell‐surface receptors are essential biomarkers and therapeutic targets, yet detecting them in native biological environments remains challenging. Turn‐on, ligand‐directed fluorescent probes have advanced the study of these receptors by enabling low‐background imaging and the sensing of interactions with binding partners. However, their broader utility is hindered by the difficulty of tuning specificity, binding affinity, and emission properties for each new target. Here, we introduce a highly modular molecular beacon (MB)‐based platform that overcomes these limitations. Building on the spatial proximity of many cell‐surface receptors and the conformational switching of MBs, we designed multivalent, ligand‐appended hairpin probes that strongly engage these receptors while undergoing stem opening and fluorescence activation at the cell surface. This design, together with the structural programmability of these single‐stranded DNA constructs, enables tuning of emission wavelength, receptor selectivity, and binding strength through simple exchange of fluorophores and ligands, and modulation of valency. For rapidly endocytosed receptors, we further demonstrate an alternative long‐stem MB design that exploits intracellular probe cleavage to trigger fluorescence. By applying these MBs to image distinct receptors, distinguish cellular states, and detect receptor–inhibitor interactions under wash‐free conditions, we demonstrate a versatile and generalizable strategy for probing cell‐surface receptors in living cells.
- 1 October 2026
- Published by Wiley in Angewandte Chemie
Open AccessLigand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions
Cell‐surface receptors are essential biomarkers and therapeutic targets, yet detecting them in native biological environments remains challenging. Turn‐on, ligand‐directed fluorescent probes have advanced the study of these receptors by enabling low‐background imaging and the sensing of interactions with binding partners. However, their broader utility is hindered by the difficulty of tuning specificity, binding affinity, and emission properties for each new target. Here, we introduce a highly modular molecular beacon (MB)‐based platform that overcomes these limitations. Building on the spatial proximity of many cell‐surface receptors and the conformational switching of MBs, we designed multivalent, ligand‐appended hairpin probes that strongly engage these receptors while undergoing stem opening and fluorescence activation at the cell surface. This design, together with the structural programmability of these single‐stranded DNA constructs, enables tuning of emission wavelength, receptor selectivity, and binding strength through simple exchange of fluorophores and ligands, and modulation of valency. For rapidly endocytosed receptors, we further demonstrate an alternative long‐stem MB design that exploits intracellular probe cleavage to trigger fluorescence. By applying these MBs to image distinct receptors, distinguish cellular states, and detect receptor–inhibitor interactions under wash‐free conditions, we demonstrate a versatile and generalizable strategy for probing cell‐surface receptors in living cells.
- Open Access
- 1 October 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e3191334
Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions
Cell‐surface receptors are essential biomarkers and therapeutic targets, yet detecting them in native biological environments remains challenging. Turn‐on, ligand‐directed fluorescent probes have advanced the study of these receptors by enabling low‐background imaging and the sensing of interactions with binding partners. However, their broader utility is hindered by the difficulty of tuning specificity, binding affinity, and emission properties for each new target. Here, we introduce a highly modular molecular beacon (MB)‐based platform that overcomes these limitations. Building on the spatial proximity of many cell‐surface receptors and the conformational switching of MBs, we designed multivalent, ligand‐appended hairpin probes that strongly engage these receptors while undergoing stem opening and fluorescence activation at the cell surface. This design, together with the structural programmability of these single‐stranded DNA constructs, enables tuning of emission wavelength, receptor selectivity, and binding strength through simple exchange of fluorophores and ligands, and modulation of valency. For rapidly endocytosed receptors, we further demonstrate an alternative long‐stem MB design that exploits intracellular probe cleavage to trigger fluorescence. By applying these MBs to image distinct receptors, distinguish cellular states, and detect receptor–inhibitor interactions under wash‐free conditions, we demonstrate a versatile and generalizable strategy for probing cell‐surface receptors in living cells.
- 1 October 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e3191334
Open AccessLigand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions
Cell‐surface receptors are essential biomarkers and therapeutic targets, yet detecting them in native biological environments remains challenging. Turn‐on, ligand‐directed fluorescent probes have advanced the study of these receptors by enabling low‐background imaging and the sensing of interactions with binding partners. However, their broader utility is hindered by the difficulty of tuning specificity, binding affinity, and emission properties for each new target. Here, we introduce a highly modular molecular beacon (MB)‐based platform that overcomes these limitations. Building on the spatial proximity of many cell‐surface receptors and the conformational switching of MBs, we designed multivalent, ligand‐appended hairpin probes that strongly engage these receptors while undergoing stem opening and fluorescence activation at the cell surface. This design, together with the structural programmability of these single‐stranded DNA constructs, enables tuning of emission wavelength, receptor selectivity, and binding strength through simple exchange of fluorophores and ligands, and modulation of valency. For rapidly endocytosed receptors, we further demonstrate an alternative long‐stem MB design that exploits intracellular probe cleavage to trigger fluorescence. By applying these MBs to image distinct receptors, distinguish cellular states, and detect receptor–inhibitor interactions under wash‐free conditions, we demonstrate a versatile and generalizable strategy for probing cell‐surface receptors in living cells.
- Open Access
- 24 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (7) , 1854-1868
Linking Biochemical and Cellular Efficacy of MERS Coronavirus Main Protease Inhibitors
Compounds that bind to the Middle East respiratory syndrome coronavirus (MERS-CoV) main protease (MPro) often produce biphasic concentration–response curves (CRCs) in biochemical assays; low concentrations activate the enzyme and high concentrations inhibit it. This biphasic behavior complicates the data analysis. Here, we compare three approaches to data analysis: fitting the Hill equation to full inhibition phase, fitting it to the inhibition phase based on the negative control, and fitting an enzyme kinetics model that incorporates dimerization and ligand binding to the complete CRC. In the latter case, cellular efficacy is predicted by extrapolation of the model to high enzyme concentrations. For compounds in our drug lead series, all three procedures yield inhibitory concentrations that are correlated with live-virus antiviral assay results. The latter procedure provides the most accurate forecast of the cellular efficacy rank. These data analysis procedures may be valuable for antiviral drug discovery against MERS-CoV MPro and other enzymes with similar kinetics.
- 24 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (7) , 1854-1868
Open AccessLinking Biochemical and Cellular Efficacy of MERS Coronavirus Main Protease Inhibitors
Compounds that bind to the Middle East respiratory syndrome coronavirus (MERS-CoV) main protease (MPro) often produce biphasic concentration–response curves (CRCs) in biochemical assays; low concentrations activate the enzyme and high concentrations inhibit it. This biphasic behavior complicates the data analysis. Here, we compare three approaches to data analysis: fitting the Hill equation to full inhibition phase, fitting it to the inhibition phase based on the negative control, and fitting an enzyme kinetics model that incorporates dimerization and ligand binding to the complete CRC. In the latter case, cellular efficacy is predicted by extrapolation of the model to high enzyme concentrations. For compounds in our drug lead series, all three procedures yield inhibitory concentrations that are correlated with live-virus antiviral assay results. The latter procedure provides the most accurate forecast of the cellular efficacy rank. These data analysis procedures may be valuable for antiviral drug discovery against MERS-CoV MPro and other enzymes with similar kinetics.
- Open Access
Linking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors
Compounds that bind to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (MPro) often produce biphasic concentration-response curves (CRCs) in biochemical assays; low concentrations activate the enzyme and high concentrations inhibit it. This biphasic behavior complicates data analysis. Here, we compare three approaches to data analysis: fitting the Hill equation to the activation phase, fitting it to the inhibition phase, and fitting an enzyme kinetics model that incorporates dimerization and ligand binding to the complete CRC. In the latter case, cellular efficacy is predicted by extrapolating the model to high enzyme concentrations. For compounds in our drug lead series, all three procedures yield inhibitory concentrations that are correlated with live-virus antiviral assays. The latter procedure provides the most accurate forecast of cellular efficacy rank. These data analysis procedures may be valuable for antiviral drug discovery against MERS-CoV MPro and other enzymes with similar kinetics.
Open AccessLinking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors
Compounds that bind to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (MPro) often produce biphasic concentration-response curves (CRCs) in biochemical assays; low concentrations activate the enzyme and high concentrations inhibit it. This biphasic behavior complicates data analysis. Here, we compare three approaches to data analysis: fitting the Hill equation to the activation phase, fitting it to the inhibition phase, and fitting an enzyme kinetics model that incorporates dimerization and ligand binding to the complete CRC. In the latter case, cellular efficacy is predicted by extrapolating the model to high enzyme concentrations. For compounds in our drug lead series, all three procedures yield inhibitory concentrations that are correlated with live-virus antiviral assays. The latter procedure provides the most accurate forecast of cellular efficacy rank. These data analysis procedures may be valuable for antiviral drug discovery against MERS-CoV MPro and other enzymes with similar kinetics.
- 1 October 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (10) , 1705-1718
Antiferroptotic Drugs Reduce sFlt-1 Release and Placenta Damage in Preeclampsia
BACKGROUND: Preeclampsia is characterized by hypertension, proteinuria, and elevated antiangiogenic sFlt-1 (soluble fms-like tyrosine kinase-1) levels. Despite extensive research, mechanisms underlying sFlt-1 dysregulation remain unclear. This hypothesis-testing study investigated whether ferroptosis, a lipid peroxidation-driven cell death mechanism, contributes to preeclamptic placental pathogenesis and sFlt-1 release, and whether drug repurposing could identify novel therapeutic options. METHODS: We analyzed oxidized phosphatidylethanolamines in human preeclamptic and healthy placental tissues using redox phospholipidomics. In placental explants, we evaluated ferroptosis effects on sFlt-1 release using Ferrostatin-1 and deferoxamine as inhibitors. We screened 6520 drugs and compounds to identify effective ferroptosis inhibitors in primary trophoblasts. Statistical analyses used Student t test and 1-way ANOVA with multiple comparison corrections. RESULTS: Preeclamptic placentas showed significant accumulation of oxidized phosphatidylethanolamines compared with controls. Inducing ferroptosis in placental explants increased sFlt-1 release, while inhibition using Ferrostatin-1 and deferoxamine reduced sFlt-1 levels ( P <0.01). Our screen identified dipyridamole and promethazine as potent ferroptosis inhibitors, reducing lipid peroxidation, preserving glutathione levels, and decreasing sFlt-1 release in preeclamptic explants. CONCLUSIONS: This study establishes placental ferroptosis as a key mechanism in early preeclampsia and demonstrates its direct link to sFlt-1 dysregulation. Our systematic drug screening approach identified approved drugs with antiferroptotic activity, suggesting a novel therapeutic strategy for preeclampsia management through drug repurposing. Further research is needed to establish optimal dosing and confirm efficacy in vivo.
- 1 October 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (10) , 1705-1718
Antiferroptotic Drugs Reduce sFlt-1 Release and Placenta Damage in Preeclampsia
BACKGROUND: Preeclampsia is characterized by hypertension, proteinuria, and elevated antiangiogenic sFlt-1 (soluble fms-like tyrosine kinase-1) levels. Despite extensive research, mechanisms underlying sFlt-1 dysregulation remain unclear. This hypothesis-testing study investigated whether ferroptosis, a lipid peroxidation-driven cell death mechanism, contributes to preeclamptic placental pathogenesis and sFlt-1 release, and whether drug repurposing could identify novel therapeutic options. METHODS: We analyzed oxidized phosphatidylethanolamines in human preeclamptic and healthy placental tissues using redox phospholipidomics. In placental explants, we evaluated ferroptosis effects on sFlt-1 release using Ferrostatin-1 and deferoxamine as inhibitors. We screened 6520 drugs and compounds to identify effective ferroptosis inhibitors in primary trophoblasts. Statistical analyses used Student t test and 1-way ANOVA with multiple comparison corrections. RESULTS: Preeclamptic placentas showed significant accumulation of oxidized phosphatidylethanolamines compared with controls. Inducing ferroptosis in placental explants increased sFlt-1 release, while inhibition using Ferrostatin-1 and deferoxamine reduced sFlt-1 levels ( P <0.01). Our screen identified dipyridamole and promethazine as potent ferroptosis inhibitors, reducing lipid peroxidation, preserving glutathione levels, and decreasing sFlt-1 release in preeclamptic explants. CONCLUSIONS: This study establishes placental ferroptosis as a key mechanism in early preeclampsia and demonstrates its direct link to sFlt-1 dysregulation. Our systematic drug screening approach identified approved drugs with antiferroptotic activity, suggesting a novel therapeutic strategy for preeclampsia management through drug repurposing. Further research is needed to establish optimal dosing and confirm efficacy in vivo.
- 21 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)
Kaposiform lymphangiomatosis (KLA) is a rare and aggressive disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by conditionally expressing the human NRAS mutation in venous and lymphatic ECs. Mutant embryos recapitulate key clinical features of KLA, including dilated lymphatics and pericardial edema, which are reversed by trametinib, a MEK inhibitor used in KLA treatment. Leveraging this model in combination with an AI-based high-throughput drug screening platform, we identify cabozantinib, a tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as promising candidates for treating KLA. Notably, both drugs normalized sprouting and migration of cultured LECs from a KLA patient. Overall, our novel zebrafish model provides a powerful platform to dissect KLA pathogenesis and identify new therapeutic avenues.
- 21 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)
Kaposiform lymphangiomatosis (KLA) is a rare and aggressive disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by conditionally expressing the human NRAS mutation in venous and lymphatic ECs. Mutant embryos recapitulate key clinical features of KLA, including dilated lymphatics and pericardial edema, which are reversed by trametinib, a MEK inhibitor used in KLA treatment. Leveraging this model in combination with an AI-based high-throughput drug screening platform, we identify cabozantinib, a tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as promising candidates for treating KLA. Notably, both drugs normalized sprouting and migration of cultured LECs from a KLA patient. Overall, our novel zebrafish model provides a powerful platform to dissect KLA pathogenesis and identify new therapeutic avenues.
- Open Access
A Structure-Based Computational Pipeline for Broad-Spectrum Antiviral Discovery
The rapid emergence of viruses with pandemic potential continues to pose a threat to public health worldwide. With the typical drug discovery pipeline taking an average of 5–10 years to reach clinical readiness, there is an urgent need for strategies to develop broad-spectrum antivirals that can target multiple viral family members and variants of concern. We present a structure-based computational pipeline designed to identify and evaluate broad-spectrum inhibitors across viral family members for a given target in order to support spectrum breadth assessment and prioritization in lead optimization programs. This pipeline comprises three key steps: (1) an automated search to identify viral sequences related to a specified target construct, (2) pose prediction leveraging any available structural data, and (3) scoring of protein-ligand complexes to estimate antiviral activity breadth. The pipeline is implemented using the drugforge package: an open-source toolkit for structure-based antiviral discovery. To validate this framework, we retrospectively evaluated two overlapping datasets of ligands bound to the SARS-CoV-2 and MERS-CoV main protease (M pro ), observing useful predictive power with respect to experimental binding affinities. Additionally, we screened known SARS-CoV-2 M pro inhibitors against a panel of human and non-human coronaviruses, demonstrating the potential of this approach to assess broad-spectrum antiviral activity. Our computational strategy aims to accelerate the identification of antiviral therapies for current and emerging viruses with pandemic potential, contributing to global preparedness for future outbreaks.
Open AccessA Structure-Based Computational Pipeline for Broad-Spectrum Antiviral Discovery
The rapid emergence of viruses with pandemic potential continues to pose a threat to public health worldwide. With the typical drug discovery pipeline taking an average of 5–10 years to reach clinical readiness, there is an urgent need for strategies to develop broad-spectrum antivirals that can target multiple viral family members and variants of concern. We present a structure-based computational pipeline designed to identify and evaluate broad-spectrum inhibitors across viral family members for a given target in order to support spectrum breadth assessment and prioritization in lead optimization programs. This pipeline comprises three key steps: (1) an automated search to identify viral sequences related to a specified target construct, (2) pose prediction leveraging any available structural data, and (3) scoring of protein-ligand complexes to estimate antiviral activity breadth. The pipeline is implemented using the drugforge package: an open-source toolkit for structure-based antiviral discovery. To validate this framework, we retrospectively evaluated two overlapping datasets of ligands bound to the SARS-CoV-2 and MERS-CoV main protease (M pro ), observing useful predictive power with respect to experimental binding affinities. Additionally, we screened known SARS-CoV-2 M pro inhibitors against a panel of human and non-human coronaviruses, demonstrating the potential of this approach to assess broad-spectrum antiviral activity. Our computational strategy aims to accelerate the identification of antiviral therapies for current and emerging viruses with pandemic potential, contributing to global preparedness for future outbreaks.
- Open Access
- 3 November 2024
- Published by Springer Nature
WNV NS2B-NS3 fluorescence single point v1
Purpose: performing single point test of selected compounds from screening experiment libraries containing serine-targeting fragments and serine protease inhibitors against WNV NS2B/NS3 to find warheads and candidates for medicinal optimization General description: This protocol details the fluorescent assays for WNV NS2B/NS3 cleavage of substrate Bz-Nle-KRR-AMC peptide. This method measures the fluorescence from the released AMC product as a result of the enzymatic reaction. When hydrolyzed, AMC is liberated from the peptide substrate. Excitation of AMC at 350 nm emits a resonant energy of 450 nm. When the enzyme is inhibited, the fluorescence signal will decrease as a result of lower enzyme activity. The screening method is validated by calculating the Z prime number of each plate, and the percentage of inhibition is calculated and then evaluated for inhibitory efficacy. Outcome: hits were selected from screening assays with more than 50% inhibition
- 3 November 2024
- Published by Springer Nature
Open AccessWNV NS2B-NS3 fluorescence single point v1
Purpose: performing single point test of selected compounds from screening experiment libraries containing serine-targeting fragments and serine protease inhibitors against WNV NS2B/NS3 to find warheads and candidates for medicinal optimization General description: This protocol details the fluorescent assays for WNV NS2B/NS3 cleavage of substrate Bz-Nle-KRR-AMC peptide. This method measures the fluorescence from the released AMC product as a result of the enzymatic reaction. When hydrolyzed, AMC is liberated from the peptide substrate. Excitation of AMC at 350 nm emits a resonant energy of 450 nm. When the enzyme is inhibited, the fluorescence signal will decrease as a result of lower enzyme activity. The screening method is validated by calculating the Z prime number of each plate, and the percentage of inhibition is calculated and then evaluated for inhibitory efficacy. Outcome: hits were selected from screening assays with more than 50% inhibition